ReviewApplied biochemistry and biotechnology2026
Transferosomes as Advanced Nanocarriers for Enhanced Drug Delivery in Skin Cancer Therapy: A Comprehensive Review.
Review in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanotechnologies for Skin Drug Delivery: Polymeric, Bio-Based, and Hybrid Nanocarriers with Clinical and Translational Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin cancer is one of the most prevalent malignancies worldwide, posing significant challenges to effective treatment due to limited drug penetration, systemic toxicity, and patient non-compliance. Transferosomes, a class of ultra-deformable vesicular carriers, have emerged as a promising strategy to overcome the skin barrier and improve topical and transdermal drug delivery. This review discusses the structural composition, preparation techniques, and physicochemical properties of transferosomes, emphasizing their unique mechanism of skin penetration. We summarize current research on transferosome-based formulations for delivering chemotherapeutics, photosensitizers, and natural bioactives targeting various skin cancers, including melanoma, basal cell carcinoma, and squamous cell carcinoma. Comparative analyses highlight the advantages of transferosomes over conventional vesicular systems such as liposomes and niosomes, including improved skin permeability, enhanced drug retention, and reduced systemic toxicity. Preclinical and limited clinical studies demonstrate their potential in achieving localized and sustained anticancer effects. Challenges related to formulation stability, large-scale production, and clinical translation are discussed, along with emerging approaches such as ligand functionalization and microneedle-assisted delivery. Collectively, transferosomes represent a versatile and effective nanocarrier system that holds great promise for improving the therapeutic outcomes of skin cancer treatment.
Indexed as
Identifiers
41637041What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.